University of Kansas Medical Center: Breast Neoplasms trials

The registry lists 28 Breast Neoplasms studies with University of Kansas Medical Center as lead sponsor. 5 are open to participants now and 9 have results posted.

Phase 1 4Phase 2 16No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBCNot yet recruitingNCT07743632Phase 2
• De-Escalation of Axillary Management in Advanced Nodal DiseaseNot yet recruitingNCT07643584Phase 2
• Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerRecruitingNCT07220135Phase 2
• Efficacy of Point Of Service Testing in MBCRecruitingNCT03983577Not applicable
• Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier RegistryRecruitingNCT02302742
• KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural PracticeCompletedNCT04763824Not applicableResults posted
• Sexual Health Empowerment for Women's HealthActive, not recruitingNCT03984695Not applicableResults posted
• Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast CancerActive, not recruitingNCT03639948Phase 2Results posted
• Pilot Study of the Effect of Duavee® on Benign Breast Tissue ProliferationCompletedNCT02729701Phase 2Results posted
• Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 ExpressionCompletedNCT00944047Phase 2Results posted
• Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.CompletedNCT00921115Phase 2Results posted
• Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast CancerCompletedNCT00853996Phase 2Results posted
• Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone TherapyTerminatedNCT00759642Phase 2Results posted
• LY353381 in Preventing Breast Cancer in Women With HyperplasiaCompletedNCT00005879Phase 2Results posted
• Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBCActive, not recruitingNCT05645380Phase 2
• Alpelisib And Sacituzumab Govitecan For Treatment Of Breast CancerActive, not recruitingNCT05143229Phase 1
• Phase IIB Trial of Bazedoxifene Plus Conjugated EstrogensActive, not recruitingNCT04821141Phase 2
• Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerTerminatedNCT03709082Phase 1/2
• Omission of Radiation in Patients With Her-2 Positive Breast CancerActive, not recruitingNCT03460067Not applicable
• Feasibility of High Levels of Energy Expenditure From Physical Activity for Breast Cancer SurvivorsCompletedNCT02963740Not applicable
• Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal IrradiationActive, not recruitingNCT02958774Not applicable
• Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer PatientsStatus unknownNCT02488187Not applicable
• Rural Women Connecting for Better HealthCompletedNCT01441011Not applicable
• Lapatinib and RAD-001 for HER2 Positive Metastatic Breast CancerStatus unknownNCT01283789Phase 2
• Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast CancerStatus unknownNCT00491816Phase 2
• Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal WomenCompletedNCT00056082Phase 2
• Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast CancerCompletedNCT00033345Phase 1
• Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast CancerCompletedNCT00005886Phase 1